The thymosin alpha 1 COVID dialysis trial did not establish that the peptide prevents COVID-19. Its final study record lists five infections among 91 treated patients and seven among 98 controls. Those small counts cannot support a dependable promise of protection.

The study involved people receiving kidney dialysis, a treatment that filters blood when kidneys fail. It does not establish protection for healthy holiday travelers or a replacement for vaccination or infection treatment.

What the thymosin alpha 1 COVID dialysis trial asked

Could thymalfasin reduce COVID-19 infections or their severity in people needing long-term dialysis? Thymalfasin is the medicine name for thymosin alpha-1, a peptide, or short chain of protein building blocks.

Tuthill and colleagues' preliminary report in International Immunopharmacology, 2023, described a pilot, a small study testing whether a larger trial might be worthwhile. Frequent dialysis-center visits and serious underlying illness made this a particular risk group. The broader immune-support claims ask a different question.

Who joined, and for how long?

Eligible participants were adults aged 18 or older receiving dialysis at least twice weekly, with treatment expected to continue indefinitely. The paper describes five dialysis centers around Kansas City.

People already testing positive for COVID-19 were excluded. So were prior transplant recipients and people with active autoimmune disease taking medicines that reduce immune activity. Autoimmune disease means immunity attacks the body's own tissues. Short-term dialysis and an expected kidney transplant within six months also excluded participation.

Random assignment, meaning chance determined treatment, compared thymalfasin with usual care without it. This was open-label: patients and staff knew the assignments. Controls received no placebo, or dummy injection.

The study regimen was 1.6 mg injected under the skin twice weekly for eight weeks, followed by four more months of observation. That describes the experiment; a prescriber sets any individual dose.

The preliminary abstract reports 194 randomized patients, while its body says 200. The final registry, a public study record, instead reports 189: 91 treated and 98 controls. These totals belong to their respective reports.

What counted as an infection?

The primary endpoint, the main result chosen beforehand, was documented COVID-19 infection. The paper required symptoms raising suspicion plus PCR confirmation, a laboratory test for the virus's genetic material. The registry's outcome window was six months.

Vaccination complicated the original plan. Most participants received COVID vaccines at different times during the study. Researchers also planned to examine antibodies, proteins that recognize infection, in stored blood samples.

The final registry acknowledges that vaccination made antibody-based infection detection unreliable. A vaccine can generate antibodies without infection. That complicates interpretation; it does not establish that thymalfasin caused a better vaccine response. The separate vaccine-study explainer covers those experiments.

NCT04428008 results: five infections versus seven

Five treated patients had recorded COVID-19, compared with seven controls.

As of November 12, 2026, the day this article was written, NCT04428008's results, first posted April 21, 2026, report these final counts:

Six-month outcome Thymalfasin, n=91 Usual care, n=98
COVID-19 infection 5 7
At least one hospitalization 27 26
Non-COVID-19 infection 8 6
Death from any cause 3 7

These are participant counts, not totals of hospital visits or infection episodes. Hospitalizations and other infections did not all point toward fewer problems with treatment.

Only 12 COVID infections were recorded. The posted tables give counts without showing how uncertain the difference is or providing a test of that difference. Fewer recorded infections and deaths are observations worth investigating, rather than proof of prevention or longer survival.

The flow table lists 75 treated patients and 81 controls as completing the study. Outcome tables still use all 91 and 98. Replacing those group sizes with the completion counts would change the reported comparison.

What did the safety tables show?

An adverse event is a medical problem recorded during a study; recording it does not establish that treatment caused it. Serious events include problems such as hospitalization or death.

Safety record Thymalfasin Control
People with serious events in the preliminary paper 27 26
People with serious events in the final registry 28 of 91 26 of 98

The paper's tables included breathing failure, infections and heart problems in this medically vulnerable population. The authors reported no apparent group difference and no concerns raised by the safety-monitoring board.

The final registry's serious-event count is slightly different from the paper's. Neither count is a rate of drug-caused side effects. Neither establishes the safety of years of treatment in healthy adults.

What later evidence adds

The later registry provides final outcome counts where the preliminary paper said its main analysis was unfinished. It does not remove the limits of a small comparison with known treatment assignments or the complications introduced by vaccination.

A later large study, TESTS in BMJ, 2025, found no clear reduction in deaths from sepsis, a life-threatening response to infection that damages organs. The sepsis-trial explainer covers that separate result. A finding in sepsis cannot settle COVID prevention, just as this dialysis pilot cannot establish routine immune boosting.

What this means for a compounded prescription

The trial did not compare its study medicine with a compounded prescription. A shared ingredient name does not establish matching effects or safety.

Thymosin alpha-1 prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, prepared for an individual prescription. That is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA does not verify compounded drugs' safety, effectiveness or quality before marketing.

As of November 12, 2026, the day this article was written, HHS, the Department of Health and Human Services, has published an October 30 notice of a draft compounding policy. The draft is not legally binding. Thymosin alpha-1 is absent from its six-peptide Appendix A; the HHS policy explainer covers the ten conditions.

A licensed provider may still prescribe — that decision is between you and your doctor.

What belongs in a provider conversation?

A useful conversation connects the intended goal with the actual evidence. Dialysis care, transplant plans, medicines affecting immunity and current infection treatment all matter. This pilot supplies context, rather than a reason to replace vaccination or established infection care.

At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. If prescribed, the provider sets the individual plan and follow-up. The question remains whether evidence from these patients fits the person considering treatment.